Biotech Values

[mcbio]

GILD is clearly the leader in all-DAA genotype-2/3, but ABT remains the company to beat, IMO, in all-DAA genotype-1—see #msg-81414058.

I still think there's room for others beyond GILD and ABT, particularly in the more difficult-to-treat cirrhotic patients.